Actinium Pharmaceuticals, Inc.: Form 10-K for the period ended Dec 31, 2020
Filed with the SEC on Mar 31, 2021 and accepted by EDGAR at Mar 31, 2021, 21:00 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2020-01-01 to 2020-12-31 | $16.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2020-01-01 to 2020-12-31 | −$22.4m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2020-01-01 to 2020-12-31 | −$22.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2020-01-01 to 2020-12-31 | −$1.83 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2020-01-01 to 2020-12-31 | −$21.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2020-01-01 to 2020-12-31 | $253.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-12-31 | $63.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-12-31 | $64.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-12-31 | $66.4m | us-gaap:Assets |
| Current liabilities | At period end2020-12-31 | $4.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-12-31 | $5.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-12-31 | $61.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-21-019297. Last ingested by Listed: Oct 24, 2026, 15:12 ET. Listed shows no prices and gives no investment advice.